M&A Deal Summary

Grünenthal Acquires Valinor

On July 22, 2024, Grünenthal acquired life science company Valinor for 250M USD

Acquisition Highlights
  • This is Grünenthal’s 6th transaction in the Life Science sector.
  • This is Grünenthal’s 2nd largest (disclosed) transaction.
  • This is Grünenthal’s 4th transaction in the United States.
  • This is Grünenthal’s 1st transaction in Illinois.

M&A Deal Summary
Date 2024-07-22
Target Valinor
Sector Life Science
Buyer(s) Grünenthal
Deal Type Add-on Acquisition
Deal Value 250M USD

Target

Valinor

Chicago, Illinois, United States
Valinor is a pharmaceutical company focused on innovative commercialization of medicines. Valinor is based in Chicago, Illinois.

Search 201,157 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Grünenthal

Aachen, Germany
Category Company
Sector Life Science
DESCRIPTION

Grünenthal GmbH is an independent, family-owned, international research-based pharmaceutical company.

DEAL STATS #
Overall 8 of 8
Sector (Life Science) 6 of 6
Type (Add-on Acquisition) 6 of 6
State (Illinois) 1 of 1
Country (United States) 4 of 4
Year (2024) 1 of 1
Size (of disclosed) 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-07-14 Nebido

Leverkusen, Germany

Nebido provides treatment of male hypogonadism (testosterone deficiency) is based in Leverkusen, Germany.

Buy €500M
Mergr

Product

Company

Legal